Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2023-04-03 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金及自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhejiang Tailin Biotechnology Co., Ltd. regarding the use of part of idle raised funds and own funds for cash management. It details the approval process by the board, supervisory committee, independent directors, and the sponsor institution. It includes information about the raised funds, their usage, and the plan to invest idle funds in safe, liquid financial products. The document is a formal announcement of a financing and capital management decision, not a full financial report or audit. It does not contain financial statements or detailed financial analysis but focuses on the company's capital management activities and approvals. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive content about capital usage, not just a brief notice or regulatory filing. Confidence is high due to clear focus on capital management and investment of idle funds.
2023-04-03 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司2022年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed internal control self-evaluation report for the year 2022 of Zhejiang Tailin Biotechnology Co., Ltd., reviewed and verified by Great Wall Securities Co., Ltd. It includes comprehensive descriptions of internal control procedures, organizational structure, risk management, financial reporting controls, and defect identification standards. The document is not a full annual report but a specific audit-related evaluation focusing on internal controls and their effectiveness, including defect classifications and remediation measures. It is a standalone audit-related report rather than a general annual report or earnings release. Therefore, it fits the category of Audit Report / Information (AR). The document length (10,688 characters) and content confirm it is the report itself, not just an announcement or certification, so it is not RPA or RNS. FY 2022
2023-04-03 Chinese
2022年年度审计报告
Audit Report / Information Classification · 100% confidence The document contains an extensive audit report including an auditor's opinion, detailed financial statements (consolidated and parent company balance sheets, income statements, cash flow statements), notes to the financial statements, and detailed audit procedures. The presence of an auditor's opinion, key audit matters, and comprehensive financial data for the fiscal year ending December 31, 2022, indicates this is a full audit report. The document length is about 15,000 characters, which is consistent with a full audit report rather than a brief announcement or certification. The document is not merely announcing the publication of a report but contains the full audit content and financial statements. Therefore, the correct classification is Audit Report / Information (AR). FY 2022
2023-04-03 Chinese
2022年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2022 年度董事会工作报告' which translates to '2022 Annual Board of Directors Work Report'. It details the board's activities, meetings, resolutions, and governance practices over the year 2022. It includes financial performance summaries, meeting details, committee activities, and plans for 2023. The content focuses on the board's work and governance rather than full financial statements or audit opinions. It is a comprehensive report on board and management activities rather than a full annual report or audit report. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is about 4837 characters, which is sufficient for a detailed report but not a full annual report. Hence, the classification is MANG with high confidence.
2023-04-03 Chinese
2022年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2022 Annual Report Summary" of Zhejiang Tailin Biotechnology Co., Ltd. It contains detailed financial data for the year 2022, including revenue, net profit, assets, and quarterly financial data. It also includes business descriptions, product information, shareholder information, bond information, and audit opinions. The document is over 11,000 characters long, indicating it is a substantive report rather than a brief announcement. The presence of comprehensive financial statements and business overview aligns with the characteristics of an Annual Report (10-K). There is no indication that this is merely an announcement of a report or a certification letter, so it should not be classified as RPA or RNS. Therefore, the document is best classified as an Annual Report (10-K). FY 2022
2023-04-03 Chinese
关于续聘天健会计师事务所（特殊普通合伙）为2023年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement by Zhejiang Tailin Biotechnology Co., Ltd. regarding the reappointment of Tianjian Certified Public Accountants as the audit firm for the fiscal year 2023. It details the auditor's qualifications, independence, past performance, and the approval process by the board and independent directors. The document does not contain actual financial statements or audit results but is an announcement about the appointment of the audit firm for the upcoming year. It also mentions that the appointment is subject to approval at the 2022 annual shareholders meeting. Therefore, this document is not the audit report itself but an announcement related to audit arrangements, fitting the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report. FY 2023
2023-04-03 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.